Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyuki Uetake

Showing results (181-190 of 206) with videos related to

Pageof 21
Sort By:
Cancers|September 23, 2022
Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM TrialTakao Takahashi, Kazuyuki Ishida, Yasunori Emi, et al.
Cancer Science|June 15, 2021
Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNAKuniko Sunami, Hideaki Bando, Yasushi Yatabe, et al.
Frontiers in Oncology|September 22, 2022
Quantitative high-throughput analysis of tumor infiltrating lymphocytes in breast cancerKumiko Hayashi, Daichi Nogawa, Maki Kobayashi, et al.
Anaerobe|October 8, 2023
Clinical significance of Bacteroides fragilis as a potential prognostic factor in colorectal cancerYuriko Matsumiya, Mitsukuni Suenaga, Toshiaki Ishikawa, et al.
Clinical Colorectal Cancer|February 27, 2017
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal CancerTakayuki Yoshino, Hiroyuki Uetake, Katsuya Tsuchihara, et al.
Cancer|October 8, 2015
International collaboration between Japan and Chile to improve detection rates in colorectal cancer screeningTakuya Okada, Koji Tanaka, Hiroshi Kawachi, et al.
The American Journal of Surgical Pathology|September 2, 2020
Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial)Hideki Ueno, Megumi Ishiguro, Eiji Nakatani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal CancersRaju Kandimalla, Jianfeng Xu, Alexander Link, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2019
Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA TrialHideki Ueno, Megumi Ishiguro, Eiji Nakatani, et al.
British Journal of Cancer|January 8, 2021
Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial)Hideki Ueno, Megumi Ishiguro, Eiji Nakatani, et al.
Pageof 21

Showing results (181-190 of 206) with videos related to

Sort By:
Pageof 21
Cancers|September 23, 2022
Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM TrialTakao Takahashi, Kazuyuki Ishida, Yasunori Emi, et al.
Cancer Science|June 15, 2021
Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNAKuniko Sunami, Hideaki Bando, Yasushi Yatabe, et al.
Frontiers in Oncology|September 22, 2022
Quantitative high-throughput analysis of tumor infiltrating lymphocytes in breast cancerKumiko Hayashi, Daichi Nogawa, Maki Kobayashi, et al.
Anaerobe|October 8, 2023
Clinical significance of Bacteroides fragilis as a potential prognostic factor in colorectal cancerYuriko Matsumiya, Mitsukuni Suenaga, Toshiaki Ishikawa, et al.
Clinical Colorectal Cancer|February 27, 2017
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal CancerTakayuki Yoshino, Hiroyuki Uetake, Katsuya Tsuchihara, et al.
Cancer|October 8, 2015
International collaboration between Japan and Chile to improve detection rates in colorectal cancer screeningTakuya Okada, Koji Tanaka, Hiroshi Kawachi, et al.
The American Journal of Surgical Pathology|September 2, 2020
Optimal Criteria for G3 (Poorly Differentiated) Stage II Colon Cancer: Prospective Validation in a Randomized Controlled Study (SACURA Trial)Hideki Ueno, Megumi Ishiguro, Eiji Nakatani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal CancersRaju Kandimalla, Jianfeng Xu, Alexander Link, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2019
Prospective Multicenter Study on the Prognostic and Predictive Impact of Tumor Budding in Stage II Colon Cancer: Results From the SACURA TrialHideki Ueno, Megumi Ishiguro, Eiji Nakatani, et al.
British Journal of Cancer|January 8, 2021
Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial)Hideki Ueno, Megumi Ishiguro, Eiji Nakatani, et al.
Pageof 21